FindTrial
Sign In

Effect of silymarin in prevention of adverse effects of anti tuberculosis drugs

Effect of silymarin in prevention of adverse effects of anti tuberculosis drugs

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138903294209N1
Enrollment
60
Registered
Unknown
Start date
2010-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug induced hepatitis by anti tuberculosis. Antimycobacterial drugs

Interventions

Intervention 1: Lactose 420 mg daily in three doses for two weeks as control. Intervention 2: Silymarin 420mg daily in three doses for two weeks as intervention.
Placebo
Prevention
Lactose 420 mg daily in three doses for two weeks as control
Silymarin 420mg daily in three doses for two weeks as intervention

Sponsors

National Institute of tuberculosis and lung disease
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- New cases of pulmonary or extra pulmonary tuberculosis 2- Older than 18 years old Exclusion criteria: 1- HIV infection 2- HCV or HBV infection 3- Abnormal liver function tests at admission 4- Drug regimen without Isoniazid, Rifampin or Pirazinamide 5- Dissatisfaction of the patient 6- Pregnancy and lactation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Drug induced hepatitis. Timepoint: three times weekly. Method of measurement: Blood levels of liver function tests.—

Secondary

MeasureTime frame
Adverse effects of Silymarin. Timepoint: Daily. Method of measurement: Daily visit.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Marjani

National research institute of tuberculosis and lun disease

marjani@nritld.ac.ir+98 21 2610 9590

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026